- Vincent Bird, MD 9-6-2024- “Comprehensive Care for Kidney Stone”
- Pinaki Sarder, PHD- “Digital Pathology Meets Spatial Omics: Emerging Problems in Data Integration, Solutions and New Opportunities”
- Sheena Pramod, MD 11-10-2024- “Vascular Access Disparities in Hemodialysis”
- Abdel Alli, PHD,MPH 11-15-2024- “The C-type natriuretic peptide receptor and endothelial sodium channel axis in essential hypertension (HTN)”
- Chintan Shah, MD 1-17-2025- “Clonal Monocytosis of Renal Significance”
- Benjamin Shickel, MD 1-24-2025- “AI-Enabled Clinical Decision Support in Acute Care”
- Kawther Alquadan, MD 1-31-2025- “Belatacept: New Hope for Kidneys After Solid Organ Transplantation”
- Muna Canales,MD 2-14-2025- “Choosing Wisely in Nephrology: A Moving Target”
- Rupam Ruchi, MD 2-28-2025- “The Impact of GLP1 Receptor Agonists on Kidney Disease: Current Insights and Future Implications”
- Rohan Mehta, MD 3-28-2025- ” Coronary Artery Disease Screening in Asymptomatic Kidney Transplant Candidates: Time for Reappraisal?”
- Dr. Olanrewaju Olaoye 4-4-2025- “Insulin Stacking: How Much Risk is it with Advanced CKD/ESKD?”
- Ashutosh Shukla, MD 4-11-2025-“Comparative Effectiveness of KRT Modalities; Considerations for Discussing Casualty in Medicine”
- Andrew Slater, MD 4-25-2025- “BK Polyomarvirus and Disease”
- Ram Sinha, MD 5-2-2025- “Mental Illness in the Chronic Kidney Disease Patient Population”
- Ivette Gomez, MD 5-09-2025- “AI in Nephrology: Transforming Kidney Care”
- Daniele Rios, MD 5-16-2025- “Contrast Associated Nephropathy- Believe It or Not?”
- Htun Naing, MD 5-23-2025- “IgA Nephrology”
- Issa Haddad, MD 5-30-2025- “Emerging Role of Donor-derived Cell-Free DNA in Kidney Transplant Assessment”
- Paola Richiez, MD 6-6-2025- “Dialysis and Pregnancy”
- Sean Michael, MD 6-13-2025- “Diet and Chronic Kidney Disease”
- Shruti Shettigar, MD 6-27-2025- “The Silent Threat: Addressing Hypertensive Disorders in Maternal Care”
This lecture by Vincent Bird, MD, focuses on the comprehensive care and management of patients with kidney stone disease. The presentation provides an in-depth overview of the causes, risk factors, and pathophysiology of kidney stone formation, helping clinicians understand how different metabolic and environmental factors contribute to stone development.
Dr. Bird discusses the diagnostic process, including patient history, imaging studies, and laboratory evaluation used to identify the type and location of kidney stones. The lecture also reviews current treatment options ranging from conservative management and medical therapy to minimally invasive surgical procedures commonly used in modern urology.
In addition, the presentation highlights preventive strategies aimed at reducing recurrence, such as dietary modifications, hydration, and metabolic evaluation. Special attention is given to individualized patient care and evidence-based approaches that improve long-term outcomes for patients suffering from kidney stone disease.
Overall, this session provides valuable clinical insights for healthcare professionals interested in improving the diagnosis, treatment, and prevention of kidney stones through a comprehensive and patient-centered approach.
In this lecture, Pinaki Sarder, PhD, discusses the growing intersection between digital pathology and spatial omics technologies. The presentation highlights how advanced imaging, computational analysis, and molecular profiling are transforming the way researchers study tissues and disease at a cellular level.
Dr. Sarder examines the challenges associated with integrating large and complex datasets generated from digital pathology and spatial omics platforms. The lecture explores issues such as data standardization, computational infrastructure, and analytical methods required to effectively combine imaging data with molecular information.
Additionally, the session presents emerging solutions and innovative approaches that help overcome these challenges. By leveraging artificial intelligence, machine learning, and advanced data integration techniques, researchers can uncover new biological insights and improve disease characterization.
Overall, this lecture emphasizes the opportunities created by combining digital pathology with spatial omics, particularly in advancing biomedical research, improving diagnostic capabilities, and supporting the development of precision medicine.
In this lecture, Sheena Pramod, MD, explores disparities in vascular access among patients receiving hemodialysis, an essential treatment for individuals with advanced kidney disease. Vascular access is a critical component of effective dialysis therapy, as it allows repeated and reliable access to the bloodstream for treatment. The type and quality of vascular access can significantly influence patient outcomes, complication rates, and overall quality of life.
Dr. Pramod discusses the different types of vascular access commonly used in hemodialysis, including arteriovenous fistulas, arteriovenous grafts, and central venous catheters. The lecture explains the clinical advantages and limitations of each option, as well as current recommendations for selecting the most appropriate access for individual patients.
A central focus of the presentation is the examination of disparities in vascular access among different patient populations. Factors such as socioeconomic status, race and ethnicity, geographic location, healthcare access, referral patterns, and patient education can influence the timing of access placement and the type of access patients ultimately receive. These disparities can lead to differences in complications, hospitalization rates, and long-term outcomes.
The lecture also highlights the role of multidisciplinary care teams—including nephrologists, surgeons, nurses, and care coordinators—in improving vascular access planning and management. Strategies for addressing disparities are discussed, including earlier referral for access creation, improved patient education, policy initiatives, and system-level interventions aimed at promoting equitable access to optimal dialysis care.
Overall, this presentation emphasizes the importance of recognizing and addressing vascular access disparities in order to improve the quality, safety, and equity of care for patients undergoing hemodialysis.
In this lecture, Abdel Alli, PhD, provides an in-depth exploration of the molecular mechanisms underlying essential hypertension, with a particular focus on the interaction between the C-type natriuretic peptide (CNP) receptor and the endothelial sodium channel (ENaC) axis. Essential hypertension is a major contributor to cardiovascular disease worldwide, and understanding the pathways that regulate vascular function is critical for developing novel therapeutic approaches.
Dr. Alli discusses how endothelial sodium channels play a central role in regulating vascular tone, endothelial cell function, and sodium homeostasis. The lecture examines how abnormal activity of these channels can lead to increased vascular stiffness, elevated blood pressure, and impaired endothelial function. In parallel, the role of the C-type natriuretic peptide receptor is highlighted, showing how it modulates ENaC activity and contributes to vasodilation and blood pressure regulation.
The presentation integrates recent research findings on the CNP-ENaC axis, explaining the cellular signaling pathways involved and how disruptions in this system may contribute to the development and progression of hypertension. Dr. Alli also discusses potential therapeutic implications, emphasizing how targeting this pathway could provide innovative strategies for the prevention and management of high blood pressure, particularly in patients resistant to conventional treatments.
Overall, this lecture offers valuable insights into the complex molecular interactions that govern vascular health and blood pressure regulation, bridging basic science research with potential clinical applications in the treatment of essential hypertension.
In this lecture, Chintan Shah, MD, presents an in-depth discussion of clonal monocytosis of renal significance (CMRS), a rare but increasingly recognized hematologic condition with important implications for kidney health. The presentation explores the pathophysiology, clinical features, and diagnostic challenges associated with this disorder, emphasizing its impact on renal function and long-term patient outcomes.
Dr. Shah reviews how clonal expansions of monocytes can contribute to kidney injury through immune-mediated mechanisms, inflammation, and tissue remodeling. The lecture details current methods for identifying clonal monocytosis, including advanced laboratory testing, flow cytometry, and genetic profiling, which are essential for accurate diagnosis and differentiation from other hematologic or renal disorders.
The session also covers the spectrum of renal manifestations associated with CMRS, ranging from mild kidney dysfunction to progressive chronic kidney disease. Dr. Shah discusses treatment strategies, including targeted therapies that address the underlying clonal hematopoiesis, supportive renal care, and monitoring approaches to minimize progression and complications.
Finally, the lecture highlights emerging research and future directions, including potential biomarkers for early detection, the role of precision medicine, and ongoing clinical trials aimed at improving patient management. This session provides valuable insights for nephrologists, hematologists, and clinicians interested in the intersection of hematologic disorders and kidney disease, offering a comprehensive framework for understanding, diagnosing, and managing CMRS.
In this lecture, Benjamin Shickel, MD, provides a comprehensive overview of AI-enabled clinical decision support (CDS) systems and their transformative potential in acute care medicine. Dr. Shickel examines how AI technologies, including machine learning, natural language processing, and predictive analytics, can analyze vast amounts of patient data in real time to assist clinicians in identifying critical conditions, predicting deterioration, and optimizing treatment strategies.
The lecture details the practical applications of AI in acute care, such as early warning systems for sepsis, automated risk stratification for ICU patients, and predictive modeling for post-surgical complications. Dr. Shickel also addresses challenges to implementation, including data integration from multiple sources, algorithm transparency, regulatory compliance, and ethical considerations surrounding AI-driven clinical decisions.
Additionally, the session explores case studies demonstrating improved patient outcomes and workflow efficiency through AI-enabled CDS, highlighting the balance between technology and clinician expertise. Future directions in AI integration, such as personalized patient care and adaptive learning systems, are discussed to illustrate how AI can evolve to support complex clinical decision-making while maintaining patient safety and quality of care.
This lecture offers valuable insights for healthcare professionals, data scientists, and administrators interested in leveraging AI to enhance decision-making and improve outcomes in acute care settings.
In this lecture, Kawther Alquadan, MD, provides an in-depth overview of belatacept as an emerging therapeutic option for preserving kidney function after solid organ transplantation. Belatacept is a novel immunosuppressive agent that selectively blocks T-cell co-stimulation, offering an alternative to calcineurin inhibitors, which are associated with nephrotoxicity and long-term renal complications.
Dr. Alquadan reviews clinical evidence demonstrating belatacept’s effectiveness in preventing acute rejection and improving long-term graft survival, highlighting studies that show enhanced kidney function in transplant recipients. The lecture also addresses patient selection criteria, dosing protocols, and monitoring requirements to ensure safe and effective therapy.
Additionally, the presentation explores potential challenges, such as infection risk, cost considerations, and logistical factors, while emphasizing strategies to optimize outcomes. Practical insights are provided for integrating belatacept into transplant care plans, including combination with other immunosuppressive agents and tailoring therapy to individual patient needs.
Overall, this session offers valuable guidance for nephrologists, transplant specialists, and healthcare professionals seeking to improve post-transplant kidney outcomes and reduce the long-term complications of immunosuppressive therapy through the use of belatacept.
In this lecture, Muna Canales, MD, provides a comprehensive overview of the Choosing Wisely initiative as it applies to nephrology, emphasizing the importance of delivering high-value, evidence-based care while minimizing unnecessary interventions. The presentation addresses the dynamic nature of nephrology practice, where new research, evolving guidelines, and individualized patient factors continuously influence clinical decision-making.
Dr. Canales reviews common areas where overtesting or overtreatment occurs, such as routine laboratory studies, imaging, or invasive procedures, and provides practical strategies for clinicians to balance thorough care with resource stewardship. The lecture also highlights the role of shared decision-making, patient education, and multidisciplinary collaboration in achieving optimal outcomes.
By examining case examples, emerging recommendations, and ongoing challenges, this session equips nephrologists and other healthcare professionals with tools to apply the principles of Choosing Wisely effectively, improving patient care while promoting efficiency and sustainability in the healthcare system.
In this lecture, Rupam Ruchi, MD, provides a detailed exploration of the role of GLP-1 receptor agonists in managing kidney disease, particularly in patients with diabetes and chronic kidney disease (CKD). These agents, originally developed for glycemic control, have demonstrated cardiovascular and renal benefits, offering a promising approach to mitigating kidney disease progression.
Dr. Ruchi reviews the mechanisms by which GLP-1 receptor agonists influence kidney function, including effects on glycemic regulation, weight management, blood pressure, inflammation, and renal hemodynamics. The lecture also examines clinical trial data supporting their efficacy in reducing albuminuria and slowing CKD progression, as well as their safety profile and potential adverse effects.
Additionally, the session highlights practical considerations for incorporating GLP-1 receptor agonists into nephrology practice, including patient selection, dosing strategies, and monitoring requirements. Dr. Ruchi discusses future directions, ongoing research, and potential combination therapies that may further enhance kidney protection.
Overall, this lecture equips clinicians with the latest insights into the renal benefits of GLP-1 receptor agonists and provides guidance for integrating these therapies into comprehensive care plans for patients at risk for or living with kidney disease.
In this lecture, Rohan Mehta, MD, provides a comprehensive analysis of coronary artery disease (CAD) screening in asymptomatic patients being considered for kidney transplantation. Cardiovascular disease is a leading cause of morbidity and mortality in transplant candidates, making appropriate risk assessment essential. However, the optimal screening approach remains a topic of ongoing debate.
Dr. Mehta reviews current guidelines, including non-invasive testing modalities, invasive procedures, and the role of risk factor assessment in determining which patients require further evaluation. The lecture examines the potential benefits of early CAD detection, such as reducing perioperative complications and improving long-term cardiovascular outcomes, as well as the drawbacks, including unnecessary procedures, delays in transplantation, and procedural risks.
The session also explores emerging evidence and contemporary studies that question traditional screening practices, emphasizing the importance of individualized risk assessment and shared decision-making. Strategies for optimizing patient selection, integrating novel biomarkers, and incorporating evidence-based protocols are discussed.
Overall, this lecture encourages clinicians to critically reappraise current CAD screening practices in asymptomatic kidney transplant candidates, aiming to improve patient safety, efficiency of transplant evaluation, and long-term outcomes while minimizing unnecessary interventions.
In this lecture, Olanrewaju Olaoye, MD, provides a detailed examination of insulin stacking—the administration of multiple insulin doses in close succession—and its impact on patients with advanced chronic kidney disease (CKD) and end-stage kidney disease (ESKD). Due to reduced renal clearance and altered insulin metabolism, these patients are particularly vulnerable to hypoglycemia and other metabolic complications when standard insulin regimens are applied without adjustment.
Dr. Olaoye reviews the pharmacokinetics of different insulin types in CKD/ESKD, highlighting how delayed clearance and prolonged action can contribute to stacking. The lecture provides practical strategies for clinicians to mitigate risks, including individualized dosing, careful monitoring of blood glucose, use of continuous glucose monitoring systems, and patient education on recognizing and preventing hypoglycemia.
The session also discusses evidence-based guidelines for insulin adjustment in advanced kidney disease, as well as clinical case examples that illustrate common challenges and solutions. By emphasizing safe and personalized insulin management, this lecture equips healthcare professionals with the knowledge to reduce adverse events and improve outcomes in high-risk diabetic patients with advanced CKD or ESKD.
In this lecture, Ashutosh Shukla, MD, provides an in-depth examination of the comparative effectiveness of kidney replacement therapy (KRT) modalities, including hemodialysis, peritoneal dialysis, and kidney transplantation. The presentation focuses on understanding the clinical outcomes associated with each modality while highlighting the challenges in establishing causality in observational studies and clinical trials.
Dr. Shukla reviews key metrics for assessing KRT effectiveness, such as patient survival, quality of life, complication rates, and healthcare utilization. The lecture also explores statistical and methodological considerations for interpreting research findings, including confounding factors, selection bias, and limitations of existing evidence.
A central component of the session is guidance on discussing causality and treatment implications with patients, emphasizing the importance of clear communication, shared decision-making, and individualized care planning. Dr. Shukla provides practical examples of how clinicians can present risks and benefits, contextualize evidence, and support patients in making informed decisions regarding their therapy options.
Overall, this lecture equips nephrologists, clinicians, and healthcare professionals with the tools to critically evaluate KRT modalities, understand causal inferences in research, and effectively guide patients in selecting the most appropriate treatment for their kidney disease.
In this lecture, Andrew Slater, MD, provides a comprehensive overview of BK polyomavirus (BKPyV) and its impact on human health, with a focus on transplant nephrology. BKPyV is a latent virus that can reactivate in immunocompromised individuals, leading to significant complications, including BK virus–associated nephropathy, ureteral strictures, and allograft dysfunction.
Dr. Slater reviews the virology and pathophysiology of BKPyV, highlighting the mechanisms by which the virus infects renal epithelial cells and triggers inflammatory responses that compromise kidney function. The lecture covers risk factors for viral reactivation, including immunosuppressive regimens, patient demographics, and transplant-related variables.
The session also explores diagnostic strategies, including viral load monitoring via PCR, biopsy findings, and differential diagnosis to distinguish BK-related injury from other causes of graft dysfunction. Management approaches are discussed, such as modulation of immunosuppression, antiviral therapies, and supportive care, along with emerging therapeutic strategies and clinical research insights.
Overall, this lecture equips nephrologists, transplant specialists, and clinicians with essential knowledge to detect, monitor, and manage BK polyomavirus infections, aiming to preserve kidney function and optimize outcomes in high-risk patient populations.
This presentation, titled “Mental Illness in the Chronic Kidney Disease Patient Population,” delivered by Ram Sinha, MD on May 2, 2025, explores the intersection between mental health disorders and chronic kidney disease (CKD). The speaker discusses the prevalence of psychiatric conditions such as depression, anxiety, and cognitive impairment among patients with CKD, highlighting how these conditions often go underdiagnosed and undertreated.
The lecture outlines the bidirectional relationship between mental illness and kidney disease, emphasizing how psychological factors can influence disease progression, treatment adherence, and overall patient outcomes. Dr. Sinha reviews common risk factors, screening tools, and diagnostic challenges in identifying mental health conditions in this population.
Additionally, the presentation addresses the impact of dialysis, medication burden, and lifestyle changes on patients’ mental well-being. Evidence-based management strategies are discussed, including pharmacologic treatments, psychotherapy, interdisciplinary care models, and the importance of integrating mental health services into nephrology practice.
The session also highlights the role of healthcare providers in early recognition, patient communication, and reducing stigma associated with mental illness. The goal of the presentation is to improve awareness, enhance patient-centered care, and promote holistic management approaches for individuals living with chronic kidney disease.
In this lecture, Ivette Gomez, MD, provides a comprehensive overview of AI-driven innovations in nephrology and their potential to transform kidney care. Dr. Gomez examines how machine learning, predictive analytics, and AI-based decision support systems are being used to improve early detection of kidney disease, optimize patient risk stratification, guide treatment decisions, and enhance outcomes for patients with chronic kidney disease (CKD), acute kidney injury (AKI), and those receiving dialysis or kidney transplantation.
The lecture discusses practical implementation considerations, including integration with electronic health records, model interpretability, data quality, and regulatory and ethical challenges in AI deployment. Dr. Gomez also reviews real-world case studies and emerging research that demonstrate the clinical utility of AI in nephrology, emphasizing its potential to support precision medicine and personalized patient care.
Overall, this session equips nephrologists, healthcare providers, and researchers with insights into leveraging AI responsibly and effectively, highlighting both opportunities and limitations in transforming kidney care through advanced technology.
In this lecture, Daniele Rios, MD, provides an in-depth exploration of contrast-associated nephropathy (CAN), a potential complication of imaging studies involving iodinated contrast media. Dr. Rios reviews the current understanding of the mechanisms underlying CAN, including renal hemodynamic changes, oxidative stress, and tubular injury, while also addressing controversies and evolving perspectives regarding its incidence and clinical impact.
The lecture highlights key risk factors, such as pre-existing chronic kidney disease, diabetes, dehydration, and concomitant nephrotoxic medications, that increase susceptibility to contrast-induced renal injury. Dr. Rios discusses preventive strategies, including proper hydration protocols, minimization of contrast volume, and careful selection of contrast type, emphasizing evidence-based approaches to reduce patient risk.
Additionally, the session reviews current diagnostic criteria, monitoring recommendations, and management strategies for patients who develop CAN. By integrating recent research and clinical experience, this lecture equips nephrologists, radiologists, and healthcare providers with practical guidance for safely performing contrast-enhanced procedures while minimizing renal complications.
Overall, this presentation offers a critical appraisal of contrast-associated nephropathy, helping clinicians make informed decisions, optimize patient safety, and understand when the risks of contrast exposure are clinically significant.
In this lecture, Htun Naing, MD, delivers a comprehensive review of IgA nephropathy (IgAN), the most common primary glomerular disease worldwide. Dr. Naing discusses the underlying pathophysiology, including aberrant IgA1 glycosylation, immune complex deposition in the glomeruli, and the resulting inflammatory response that leads to kidney injury.
The lecture covers clinical features such as hematuria, proteinuria, hypertension, and variable rates of progression to chronic kidney disease. Dr. Naing reviews diagnostic approaches, including laboratory tests, imaging, and kidney biopsy findings, emphasizing their role in confirming diagnosis and guiding management.
Treatment strategies are explored in detail, including supportive care with blood pressure control and renin-angiotensin system blockade, as well as immunosuppressive therapies for select high-risk patients. Emerging therapies, including targeted biologics and novel pharmacologic agents, are discussed as promising options for slowing disease progression and improving long-term renal outcomes.
Overall, this session provides nephrologists, trainees, and healthcare professionals with a thorough understanding of IgA nephropathy, equipping them with the knowledge to diagnose effectively, implement evidence-based management, and stay informed on evolving treatment strategies.
In this lecture, Issa Haddad, MD, provides an in-depth overview of the emerging role of donor-derived cell-free DNA (dd-cfDNA) in kidney transplantation. dd-cfDNA has gained attention as a non-invasive biomarker for early detection of allograft injury, offering clinicians a tool to monitor kidney transplant recipients more precisely and potentially reduce reliance on invasive biopsies.
Dr. Haddad reviews the biological basis of dd-cfDNA, its mechanisms of release during cellular injury or rejection, and the analytical techniques used to quantify it. The lecture discusses clinical evidence supporting the utility of dd-cfDNA in identifying acute rejection, antibody-mediated injury, and subclinical graft damage before traditional laboratory or imaging markers become abnormal.
Additionally, the session covers practical considerations for integrating dd-cfDNA testing into routine transplant care, including timing of measurement, interpretation of results, and how it can inform immunosuppressive management and patient follow-up. Emerging research, limitations, and potential future applications in precision transplant medicine are also addressed.
Overall, this lecture equips nephrologists, transplant specialists, and healthcare providers with insights into how dd-cfDNA can enhance early detection of graft injury, improve patient outcomes, and guide evidence-based decision-making in kidney transplantation.
In this lecture, Paola Richiez, MD, provides a comprehensive overview of pregnancy in women receiving dialysis, highlighting the unique clinical challenges and strategies required to support maternal and fetal health. Pregnancy in dialysis patients is high-risk, with increased rates of complications such as preterm birth, intrauterine growth restriction, hypertension, and maternal morbidity.
Dr. Richiez reviews modifications to dialysis regimens that improve pregnancy outcomes, including increased dialysis frequency, careful fluid and electrolyte management, and individualized adjustments to medication and nutrition. The lecture emphasizes the importance of close monitoring of both maternal and fetal parameters, including blood pressure, laboratory markers, and fetal growth assessments.
The session also highlights the role of a multidisciplinary care team, including nephrologists, obstetricians, dietitians, and nurses, to provide coordinated, patient-centered care. Emerging evidence and case studies are discussed to illustrate best practices, optimize perinatal outcomes, and guide clinicians in managing complex scenarios.
Overall, this lecture equips healthcare professionals with practical knowledge and evidence-based strategies to safely manage pregnancy in patients on dialysis, improving both maternal and neonatal outcomes.
In this lecture, Sean Michael, MD, provides a comprehensive overview of dietary management in chronic kidney disease (CKD) and its role in improving patient outcomes. Dr. Michael discusses how nutrition influences the progression of kidney disease, cardiovascular risk, electrolyte balance, and quality of life.
The lecture reviews evidence-based dietary strategies, including individualized protein intake, sodium restriction, potassium and phosphorus management, fluid optimization, and the use of plant-based diets where appropriate. Dr. Michael also addresses patient education, adherence challenges, and cultural or lifestyle considerations in developing effective nutrition plans.
Additionally, the session explores emerging research on dietary interventions, including the impact of specific nutrients, dietary patterns, and novel approaches such as intermittent fasting and precision nutrition, on kidney function and overall health. Practical guidance for clinicians on counseling, monitoring, and adjusting dietary plans is provided.
Overall, this lecture equips nephrologists, dietitians, and healthcare professionals with the knowledge to implement nutrition-focused strategies in CKD management, promoting slowed disease progression, reduced complications, and enhanced patient well-being.
In this lecture, Shruti Shettigar, MD, provides a comprehensive overview of hypertensive disorders in maternal care, emphasizing their prevalence, clinical impact, and potential for serious maternal and fetal complications. Dr. Shettigar discusses the pathophysiology of preeclampsia, gestational hypertension, and chronic hypertension in pregnancy, highlighting the mechanisms that contribute to maternal organ dysfunction and adverse fetal outcomes.
The lecture reviews risk factors, screening methods, and diagnostic criteria, emphasizing the importance of early detection and timely intervention. Dr. Shettigar presents evidence-based management strategies, including pharmacologic therapy, close monitoring, and delivery planning, tailored to optimize both maternal and fetal safety.
Additionally, the session emphasizes the value of a multidisciplinary care approach, involving obstetricians, nephrologists, maternal-fetal medicine specialists, and nursing teams, to provide coordinated care. Case studies and real-world examples illustrate challenges in management and highlight best practices for reducing complications associated with hypertensive disorders during pregnancy.
Overall, this lecture equips healthcare professionals with the knowledge to recognize, prevent, and manage hypertensive disorders in pregnancy, aiming to improve outcomes for both mothers and their babies.